Literature DB >> 7061243

Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy.

L L Gunderson, H Sosin.   

Abstract

Following initial "curative" operative procedures for gastric carcinoma, 107 patients had planned single or multiple re-operations at the University of Minnesota. Later evidence of cancer was found in 86 patients at re-operation and/or other follow-up. Initial operative-pathologic extent of disease was correlated with incidence and patterns of failure. Distant metastasis (DM) alone was uncommon, but was found as a new component in 25.6% of the failure group. Nearly half of the peritoneal failures (PS) were localized, and when diffuse, were usually accompanied by a moderate sized local-regional failure. Local recurrence and/or regional lymph node metastasis (LF-RF) occurred as the only failure in 53.7% of the failure group if localized peritoneal failures were included, and as any component of failure in 87.8% (67.3% of the total 107 patients). Operation alone yields inadequate results for the majority of patients with gastric carcinoma. The rationale of adjuvant radiation and systemic therapy alone or in combination is discussed.

Entities:  

Mesh:

Year:  1982        PMID: 7061243     DOI: 10.1016/0360-3016(82)90377-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  109 in total

1.  Neoadjuvant therapy.

Authors:  J E Niederhuber
Journal:  Ann Surg       Date:  1999-03       Impact factor: 12.969

2.  Intensify standardized therapy for esophageal and stomach cancer in tumor hospitals.

Authors:  S J Wang; D G Wen; J Zhang; X Man; H Liu
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

3.  Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination.

Authors:  Fumiko Taguchi; Yasuo Kodera; Yasufumi Katanasaka; Kazuyoshi Yanagihara; Tomohide Tamura; Fumiaki Koizumi
Journal:  Invest New Drugs       Date:  2010-06-08       Impact factor: 3.850

4.  Clinical outcomes according to primary treatment in gastric cancer patients with peritoneal seeding.

Authors:  Jung Min Bae; Kyoung Joon Yeo; Se Won Kim; Sang Woon Kim; Sun Kyo Song
Journal:  J Gastric Cancer       Date:  2011-09-29       Impact factor: 3.720

5.  Treatment of resectable gastric cancer.

Authors:  Johan L Dikken; Cornelis J H van de Velde; Daniel G Coit; Manish A Shah; Marcel Verheij; Annemieke Cats
Journal:  Therap Adv Gastroenterol       Date:  2012-01       Impact factor: 4.409

6.  Lymph node metastases of gastric cancer. General pattern in 1931 patients.

Authors:  K Maruyama; P Gunvén; K Okabayashi; M Sasako; T Kinoshita
Journal:  Ann Surg       Date:  1989-11       Impact factor: 12.969

7.  When is curative gastrectomy justified for gastric cancer with positive peritoneal lavage cytology but negative macroscopic peritoneal implant?

Authors:  Isao Miyashiro; Ko Takachi; Yuichiro Doki; Osamu Ishikawa; Hiroaki Ohigashi; Kohei Murata; Yo Sasaki; Shingi Imaoka; Akihiko Nakaizumi; Akemi Takenaka; Hiroshi Furukawa; Masahiro Hiratsuka
Journal:  World J Surg       Date:  2005-09       Impact factor: 3.352

8.  Evaluation of internal target volume in patients undergoing image-guided intensity modulated adjuvant radiation for gastric cancers.

Authors:  A Aggarwal; S Chopra; S N Paul; R Engineer; S K Srivastava
Journal:  Br J Radiol       Date:  2013-11-28       Impact factor: 3.039

9.  Lauren Histologic Type Is the Most Important Factor Associated With Pattern of Recurrence Following Resection of Gastric Adenocarcinoma.

Authors:  Jun H Lee; Kevin K Chang; Changhwan Yoon; Laura H Tang; Vivian E Strong; Sam S Yoon
Journal:  Ann Surg       Date:  2018-01       Impact factor: 12.969

10.  Hyperthermic intraperitoneal chemotherapy (HIPEC) and neoadjuvant chemotherapy as prophylaxis of peritoneal carcinosis from advanced gastric cancer-effects on overall and disease free survival.

Authors:  Federico Coccolini; Andrea Celotti; Marco Ceresoli; Giulia Montori; Michele Marini; Fausto Catena; Luca Ansaloni
Journal:  J Gastrointest Oncol       Date:  2016-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.